Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Telaprevir Stories

2014-04-14 12:51:21

The new interferon-free, all-oral, three direct-acting-antiviral (3D) treatment regimen in development by AbbVie has achieved very high rates of virological response in patients chronically infected with hepatitis C virus (HCV) genotype 1 (GT1); according to the results of three studies presented today at the International Liver CongressTM 2014. The 3D regimen consists of the HCV NS3/4A protease inhibitor ABT-450 dosed with ritonavir, the NS5A inhibitor ABT-267, and the NS5B RNA polymerase...

2014-04-12 12:20:06

LONDON, April 12, 2014 /PRNewswire/ -- Janssen R&D Ireland (Janssen) today announced new results from cohort 2 of the Phase 2 COSMOS study demonstrating that 93 percent of patients with the hepatitis C virus (HCV) and advanced liver fibrosis (METAVIR scores F3 and F4) who were treated with simeprevir administered once daily with Gilead Sciences, Inc.'s sofosbuvir for 12 weeks achieved sustained virologic response 12 weeks after the end of treatment (SVR12). The addition of...

2014-04-02 08:32:34

OPTIMIST represents the first Phase 3 studies of the two treatments in a regimen without interferon and ribavirin CORK, Ireland, April 2, 2014 /PRNewswire/ -- Janssen R&D Ireland (Janssen) announced today that two Phase 3 trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naive and...

2014-02-02 23:02:36

ResearchMoz include new market research report "Hepatitis C Therapeutics in Major Developed Markets to 2019 - Industry Size, Shares, Growth, Trends and Forecast 2019" to its huge collection of research reports. Browse reports in Therapeutic Area - http://www.researchmoz.us/therapeutic-area-market-reports-37.html. Albany, NY (PRWEB) February 02, 2014 “Hepatitis C Therapeutics in Major Developed Markets to 2019 – Outstanding Recent Approvals and Late-Stage Pipeline to...

2014-01-16 10:01:37

Study shows safe and simpler treatment for potentially deadly, liver-damaging disease Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans than HIV/AIDS, are about to get simpler and more effective, according to new research at Johns Hopkins and elsewhere. In a study to be reported in the Jan. 16 issue of the New England Journal of Medicine, researchers say combination treatments involving a pair of experimental, oral antiviral...

2013-11-26 23:32:05

AllMed webinar provides in-depth review of the latest in the standard of care for the treatment of hepatitis C virus (HCV) infection. Portland, OR (PRWEB) November 26, 2013 As the treatment of HCV continues to evolve, new and increasingly complex protocols present additional challenges in providing optimal care while meeting the unique needs of individual patients with HCV. During a recent webinar hosted by AllMed Healthcare Management, Dr. Anca Pop, board-certified gastroenterologist and...

2013-11-25 04:21:07

OLYSIO(TM) is the first once-daily protease inhibitor approved for the treatment of chronic hepatitis C in a combination antiviral regimen for adults with compensated liver disease TITUSVILLE, N.J., Nov. 25, 2013 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP (Janssen), announced today the U.S. Food and Drug Administration (FDA) has approved OLYSIO((TM)) (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an...

2013-11-22 20:22:56

OLYSIO(TM) is the first once-daily protease inhibitor approved for the treatment of chronic hepatitis C in a combination antiviral regimen for adults with compensated liver disease TITUSVILLE, N.J., Nov. 22, 2013 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP (Janssen), announced today the U.S. Food and Drug Administration (FDA) has approved OLYSIO((TM)) (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an...

2013-11-21 08:28:22

Surveyed Physicians Expect Nearly 20 Percent of Their Actively Treated HCV Patients to Be On a Newly Approved Regimen, According to a New Report from BioTrends Research Group EXTON, Pa., Nov. 21, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, following the launches of Gilead's sofosbuvir and Janssen/Medivir's simeprevir in the United States, currently marketed triple (Vertex's...

2013-11-04 08:27:37

Presented: November 5, 2013 -- Walter E. Washington Convention Center, Washington, DC WASHINGTON, Nov. 4, 2013 /PRNewswire/ -- In this abstract to be presented at the annual meeting of the American Association for the Study of Liver Diseases, researchers from Japan provided 12-week results from their phase III study of an all-oral treatment regimen. In their presentation at The Liver Meeting® they will also provide 24-week results. The group administered a combined treatment of...